Literature DB >> 10212505

Echocardiographic mitral valve prolapse in cavalier King Charles spaniels: epidemiology and prognostic significance for regurgitation.

H D Pedersen1, K A Lorentzen, B O Kristensen.   

Abstract

This study investigated the epidemiology and prognostic significance of mitral valve prolapse, detected by ultrasonography, in 153 cavalier King Charles spaniels which were screened consecutively during a period of one year. Seventy-five of the dogs, which had either no murmur or a grade I murmur on screening, were reexamined three years later. The screening revealed that 82 per cent of the dogs aged one to three years and 97 per cent of the dogs over three years had various degrees of mitral valve prolapse. The presence and severity of the condition were independent of gender but correlated positively with age and negatively with bodyweight. The degree of mitral valve prolapse at screening correlated with the regurgitation status (murmur intensity and size of the regurgitant jets) at re-examination and with the percentage increase in the left ventricular end diastolic diameter over the three-year period. The presence of a grade I murmur was not a useful prognostic indicator.

Entities:  

Mesh:

Year:  1999        PMID: 10212505     DOI: 10.1136/vr.144.12.315

Source DB:  PubMed          Journal:  Vet Rec        ISSN: 0042-4900            Impact factor:   2.695


  19 in total

Review 1.  Differentiating the aging of the mitral valve from human and canine myxomatous degeneration.

Authors:  Patrick S Connell; Richard I Han; K Jane Grande-Allen
Journal:  J Vet Cardiol       Date:  2012-02-24       Impact factor: 1.701

Review 2.  Comparative pathology of human and canine myxomatous mitral valve degeneration: 5HT and TGF-β mechanisms.

Authors:  Mark A Oyama; Chad Elliott; Kerry A Loughran; Alexander P Kossar; Estibaliz Castillero; Robert J Levy; Giovanni Ferrari
Journal:  Cardiovasc Pathol       Date:  2020-01-07       Impact factor: 2.185

3.  Evaluation of the Swedish breeding program for cavalier King Charles spaniels.

Authors:  Tobias Lundin; Clarence Kvart
Journal:  Acta Vet Scand       Date:  2010-09-23       Impact factor: 1.695

4.  Asymptomatic heart valve dysfunction in healthy middle-aged companion dogs and its implications for cardiac aging.

Authors:  Silvan R Urfer; Tammi L Kaeberlein; Susan Mailheau; Philip J Bergman; Kate E Creevy; Daniel E L Promislow; Matt Kaeberlein
Journal:  Geroscience       Date:  2017-01-14       Impact factor: 7.713

Review 5.  Myxomatous mitral valve disease in dogs: does size matter?

Authors:  Heidi G Parker; Paul Kilroy-Glynn
Journal:  J Vet Cardiol       Date:  2012-02-20       Impact factor: 1.701

6.  Circulating MiR-30b-5p is upregulated in Cavalier King Charles Spaniels affected by early myxomatous mitral valve disease.

Authors:  Mara Bagardi; Sara Ghilardi; Valentina Zamarian; Fabrizio Ceciliani; Paola G Brambilla; Cristina Lecchi
Journal:  PLoS One       Date:  2022-07-11       Impact factor: 3.752

7.  The Mitral INsufficiency Echocardiographic score: A severity classification of myxomatous mitral valve disease in dogs.

Authors:  Tommaso Vezzosi; Giovanni Grosso; Rosalba Tognetti; Valentina Meucci; Valentina Patata; Federica Marchesotti; Oriol Domenech
Journal:  J Vet Intern Med       Date:  2021-05-05       Impact factor: 3.333

8.  Prevalence of disorders recorded in Cavalier King Charles Spaniels attending primary-care veterinary practices in England.

Authors:  Jennifer F Summers; Dan G O'Neill; David B Church; Peter C Thomson; Paul D McGreevy; David C Brodbelt
Journal:  Canine Genet Epidemiol       Date:  2015-04-18

9.  Clinical severity score system in dogs with degenerative mitral valve disease.

Authors:  J López-Alvarez; J Elliott; D Pfeiffer; Y-M Chang; M Mattin; W Moonarmart; M J Hezzell; A Boswood
Journal:  J Vet Intern Med       Date:  2015 Mar-Apr       Impact factor: 3.333

10.  Reliability and identification of aortic valve prolapse in the horse.

Authors:  Gayle D Hallowell; Mark Bowen
Journal:  BMC Vet Res       Date:  2013-01-11       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.